Business
Exagen Inc. Announces Proposed Public Offering of Common Stock
CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its common stock. In connection with the offering, Exagen intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares of common stock to be sold in the offering will be sold by Exage
About this update from Exagen Inc.
[{"type":"image","alt":"Exagen Inc.","displaySize":"","headline":null,"caption":"Exagen Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/14dcf296c8db7fb07c938fd3210e3716"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/s5kZKXkkz0E4OBFbX6qSYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/14dcf296c8db7fb07c938fd3210e3716","width":300,"height":84}},"lazy":false},{"type":"text","content":"CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its common stock. In connection with the offering, Exagen intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares of common stock to be sold in the offering will be sold by Exagen. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.","length":697,"tagName":"p"},{"type":"text","content":"Canaccord Genuity is acting as sole bookrunner for the offering.","length":64,"tagName":"p"},{"type":"text","content":"The public offering will be made pursuant to a shelf registration statement on Form S-3 (including a base prospectus) that was filed with the Securities and Exchange Commission (the “SEC”) on November 17, 2023, as amended on November 27, 2023, and declared effective by the SEC on November 29, 2023. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. The offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained from Canaccord Genuity LLC, Attention: Syndication Department, 1 Post Office Square, Suite 3000, Boston, MA 02109, or by email at [email protected]. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.","length":897,"tagName":"p"},{"type":"text","content":"This press release shall not cons...